CDC Recommends Pfizer Vaccine For 5-11 Year Olds

November 3, 2021

Last night, the CDC endorsed the ACIP’s recommendation to allow vaccination in 5-11-year-olds using the Pfizer-BioNTech vaccine. 5-11-year-olds will be administered two 10-microgram doses; those 12+ years of age are given two 30-microgram doses.

During the ACIP meeting preceding the CDC’s endorsement, data was reviewed from Pfizer’s clinical trial in which 3,100 children ages 5-11 were given a low dose of the Pfizer vaccine. The trial demonstrated 91% efficacy in preventing COVID-19 within this age group; vaccine side effects were mild, self-limiting, and similar to side effects seen in older age groups. Moreover, antibody responses were comparable to those seen in 16-25-year-olds.

While children have been shown to fare a COVID-19 infection better than adults, the Delta surge brought on an influx of pediatric COVID-19 cases. It is still unknown what the long-term ramifications may be of COVID-19 in children. As of recent, close to 2 million COVID-19 cases have been reported in 5-11-year-olds; within this age group, over 2,000 children have developed MIS-C after their COVID-19 infection. Of all pediatric cases, those in the 5-11 age range have experienced the highest number of MIS-C cases.
In regard to myocarditis in children, the ACIP clarified that a COVID-19 infection poses a bigger risk to heart complications than vaccination.

Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.